Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 278 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment of Type I Diabetes Mellitus. Clear all
Completed Phase 1Phase 2 Interventional Results available

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes

NCT00645840
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anakinra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Telemedicine Monitoring of Nocturnal Incidents

NCT04328896
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia
Interventions
CGM-Tele-monitoring
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 7, 2026, 9:08 PM EDT
Recruiting No phase listed Observational

Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Syosset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 7, 2026, 9:08 PM EDT
Withdrawn Not applicable Interventional

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

NCT04227626
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
GlucoSTAT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

NCT00957268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT04540536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Noncompliance, Patient
Interventions
Continuous Glucose Monitoring, Secure texting
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 3 Interventional Results available

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

NCT01881828
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin (glucophage), oral placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 19 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

NCT00913497
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
insulin glulisine, insulin aspart
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
4 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

NCT00139659
View directory record Official record
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

NCT03895996
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AVT001, Placebo
Drug · Other
Lead sponsor
Avotres Inc.
Industry
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

NCT01293461
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
Interventions
CBX129801, Placebo
Drug
Lead sponsor
Cebix Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Escondido, California • Tustin, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 4 Interventional

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

NCT01028287
View directory record Official record
Conditions
Diabetic Nephropathy, Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02367066
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AR-C165395XX, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Integrating Community Health Workers Into the Care of Children With Type 1 Diabetes

NCT03475108
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Psychosocial Problem, Compliance, Patient, Diabetes Mellitus
Interventions
Community Health Worker added to diabetes team
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 18 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional Results available

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

NCT03195140
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Predictive Low Glucose Suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Santa Barbara, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 7, 2026, 9:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

NCT05119140
View directory record Official record
Conditions
Ulcerative Colitis (Disorder)
Interventions
Hydroxychloroquine, Mesalamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

NCT00372814
View directory record Official record
Conditions
Diabetes Mellitus, Insulin Dependent
Interventions
Intensive Home-Based Family Therapy, Supportive Telephone Calls
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Not applicable Interventional Results available

Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

NCT05644730
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Fusion closed loop glucose control system
Device
Lead sponsor
Ideal Medical Technologies
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

NCT00529399
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 1 Interventional

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

NCT06272695
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Volagidemab
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Deigo, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 7, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

NCT03878277
View directory record Official record
Conditions
Type1diabetes, Type1 Diabetes Mellitus, Diabetic Kidney Disease, Juvenile Diabetes, Diabetic Nephropathies, Diabetes Complications, Diabetes, Autoimmune
Interventions
Starbucks® Cold brew - 325ml bottle
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 7, 2026, 9:08 PM EDT